Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber exercised options covering 5,000 shares on September 29, 2026, at an exercise price of $6.08 per share, and acquired 5,000 common shares. He reported 9,740 directly held common shares following the transaction. The option was granted under Rallybio's 2021 Equity Incentive Plan and vests in 48 equal monthly installments until fully vested on February 14, 2029.
Rallybio Corp (RLYB) director Hui Liu exercised options to acquire 3,562 and 8,482 common shares on September 24, 2026, at exercise prices of $2.38 and $7.60 per share, respectively. The corresponding common-stock entries report acquisition of those same share amounts. The 8,482-share option was issued under Rallybio’s 2021 Equity Incentive Plan in lieu of $47,500 in retainer fees.
Rallybio Corp (RLYB) director Wendy Chung exercised stock options into common shares. On September 16, 2026, she exercised options for 3,562 shares of common stock at an exercise price of $2.38 per share, converting an option position into directly held stock.
The exercised option for 3,562 underlying shares now shows 0 options remaining from that grant, while her direct ownership in Rallybio common stock is reported as 3,562 shares following the transaction. No Rule 10b5-1 trading plan is reported for this activity.
Rallybio Corporation (RLYB) filed an amended Form S-4 to register shares of common stock to be issued in its all‑stock merger with Avenzo Therapeutics, Inc. Based on the assumed exchange ratio of 0.5020, Rallybio expects to issue approximately 193,644,387 shares of common stock and options to purchase 19,136,431 shares, before a proposed reverse stock split. Avenzo stockholders (excluding new investors) are expected to own about 56.6% of the combined company, Rallybio stockholders about 2.8%, and investors in a concurrent Avenzo financing about 40.6%, assuming $215.0 million of financing proceeds.
Rallybio calculates Rallybio Net Cash of about $82.2 million as of August 15, 2026 and plans to distribute substantially all Rallybio Net Cash to pre‑closing stockholders via cash “Parent Distributions” and longer‑dated contingent value rights (CVRs) tied to monetization of its legacy assets and a prior sale to Recursion. Existing Rallybio shares remain outstanding but will be heavily diluted, with closing conditioned on stockholder approval of share issuance, reverse split, name change to Avenzo Therapeutics, Inc., and Nasdaq listing of the combined company under ticker AVZO.
Rallybio Corp (RLYB) reported a change in the work arrangement of its Chief Financial Officer, Jonathan LieberSeptember 15, 2026base salary of $420,000Avenzo Therapeutics, Inc.May 31, 2026
Rallybio Corp (symbol: RLYB) is the issuer of record for a Form S-4/A filing submitted to the SEC.
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of Rallybio Corporation common stock. As of June 30, 2026, the group may be deemed to beneficially own 188,422 shares of common stock, representing 3.56% of the outstanding class. All 188,422 shares are reported with shared voting and shared dispositive power, and none with sole power. The filing states that the group holds 5% or less of Rallybio’s common stock, reflecting its status as a significant but non‑controlling shareholder.
Cormorant Asset Management, LP and Bihua Chen report that they no longer beneficially own any shares of Rallybio Corp common stock. They state beneficial ownership of 0 shares, representing 0.0% of Rallybio’s common stock, with no sole or shared voting or dispositive power.
The ownership percentages are based on 5,298,137 shares of Rallybio common stock outstanding as of May 8, 2026, as referenced from Rallybio’s Quarterly Report for the period ended March 31, 2026. The filers also indicate that the statement should not be construed as an admission of beneficial ownership for purposes of Section 13.
Rallybio Corp received an amended Schedule 13G filing from Balyasny Asset Management L.P. and related entities reporting that they are not beneficial owners of Rallybio’s common stock. The reporting group, including BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, reports beneficial ownership of 0 shares, representing approximately 0% of the outstanding common stock, based on 5,298,137 shares outstanding as of May 8, 2026 as reported by Rallybio. The filers state they have no sole or shared voting or dispositive power over any Rallybio shares and confirm ownership of 5 percent or less of the class.
FMR LLC and Abigail P. Johnson report beneficial ownership of Rallybio Corp common stock. As of 06/30/2026, they beneficially owned 794,720 shares of common stock, representing 15.0% of the class identified by CUSIP 75120L209.
FMR LLC has sole voting power over 794,720 shares and no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over 794,720 shares. Within this position, Fidelity Growth Company Commingled Pool held 265,132 shares, equal to 5.0% of Rallybio’s outstanding common stock as of 06/30/2026.